1. Home
  2. MRNA vs CHE Comparison

MRNA vs CHE Comparison

Compare MRNA & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRNA
  • CHE
  • Stock Information
  • Founded
  • MRNA 2010
  • CHE 1970
  • Country
  • MRNA United States
  • CHE United States
  • Employees
  • MRNA N/A
  • CHE N/A
  • Industry
  • MRNA Biotechnology: Biological Products (No Diagnostic Substances)
  • CHE Medical/Nursing Services
  • Sector
  • MRNA Health Care
  • CHE Health Care
  • Exchange
  • MRNA Nasdaq
  • CHE Nasdaq
  • Market Cap
  • MRNA 10.6B
  • CHE 8.8B
  • IPO Year
  • MRNA 2018
  • CHE N/A
  • Fundamental
  • Price
  • MRNA $24.25
  • CHE $571.36
  • Analyst Decision
  • MRNA Hold
  • CHE Buy
  • Analyst Count
  • MRNA 20
  • CHE 1
  • Target Price
  • MRNA $51.94
  • CHE $674.00
  • AVG Volume (30 Days)
  • MRNA 8.3M
  • CHE 131.0K
  • Earning Date
  • MRNA 05-01-2025
  • CHE 04-23-2025
  • Dividend Yield
  • MRNA N/A
  • CHE 0.35%
  • EPS Growth
  • MRNA N/A
  • CHE 10.48
  • EPS
  • MRNA N/A
  • CHE 20.53
  • Revenue
  • MRNA $3,177,000,000.00
  • CHE $2,488,997,000.00
  • Revenue This Year
  • MRNA N/A
  • CHE $9.04
  • Revenue Next Year
  • MRNA $22.14
  • CHE $6.68
  • P/E Ratio
  • MRNA N/A
  • CHE $27.88
  • Revenue Growth
  • MRNA N/A
  • CHE 8.52
  • 52 Week Low
  • MRNA $23.15
  • CHE $512.12
  • 52 Week High
  • MRNA $170.47
  • CHE $623.61
  • Technical
  • Relative Strength Index (RSI)
  • MRNA 38.02
  • CHE 46.01
  • Support Level
  • MRNA $23.70
  • CHE $568.44
  • Resistance Level
  • MRNA $28.52
  • CHE $583.37
  • Average True Range (ATR)
  • MRNA 1.36
  • CHE 14.07
  • MACD
  • MRNA -0.09
  • CHE 0.39
  • Stochastic Oscillator
  • MRNA 11.11
  • CHE 60.32

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

About CHE Chemed Corp

Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.

Share on Social Networks: